Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-α activation in cultured human female hepatocytes

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 307, Issue 2, 2014, Pages

  McIntosh, Avery L ^a   Huang, Huan ^a   Storey, Stephen M ^a   Landrock, Kerstin K ^a   Landrock, Danilo ^a   Petrescu, Anca D ^a   Gupta, Shipra ^b   Atshaves, Barbara P ^b   Kier, Ann B ^a   Schroeder, Friedhelm ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Michigan State University   (United States)

Author keywords

Fatty acid; Fibrate; Hepatocyte; Liver fatty acid binding protein; oxidation

Indexed keywords

FATTY ACID; FIBRATE; HEPATOCYTE; LIVER FATTY ACID-BINDING PROTEIN; Β-OXIDATION;

APOLIPOPROTEIN B-100; CELLS, CULTURED; CHOLESTEROL ESTERS; FATTY ACID-BINDING PROTEINS; FATTY ACIDS; FEMALE; FENOFIBRATE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VARIATION; HEPATOCYTES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOGENESIS; MIDDLE AGED; OXIDATION-REDUCTION; PHENOTYPE; PPAR ALPHA; PROTEIN BINDING; PROTEIN TRANSPORT; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 84904299363     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00369.2013     Document Type: Article

References (67)

1. Atshaves BP, Martin GG, Hostetler HA, McIntosh AL, Kier AB, Schroeder F. Liver fatty acid binding protein (L-FABP) and Dietary Obesity. J Nutr Biochem 21: 1015-1032, 2010.
2. Atshaves BP, McIntosh AL, Lyuksyutova OI, Zipfel WR, Webb WW, Schroeder F. Liver fatty acid binding protein gene ablation inhibits branched-chain fatty acid metabolism in cultured primary hepatocytes. J Biol Chem 279: 30954-30965, 2004.
3. Atshaves BP, Payne HR, McIntosh AL, Tichy SE, Russell D, Kier AB, Schroeder F. Sexually dimorphic metabolism of branched chain lipids in C57BL/6J mice. J Lipid Res 45: 812-830, 2004.
4. Bordewick U, Heese M, Borchers T, Robenek H, Spener F. Compartmentation of hepatic fatty-acid-binding protein in liver cells and its effect on microsomal phosphatidic acid biosynthesis. Biol Chem Hoppe Seyler 370: 229-238, 1989.
5. Brouillette C, Bose Y, Perusse L, Gaudet D, Vohl MC. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J Hum Genet 49: 424-432, 2004.
6. Cai J, Lucke C, Chen Z, Qiao Y, Klimtchuk E, Hamilton JA. Solution structure and backbone dynamics of human liver fatty acid binding protein: fatty acid binding revisited. Biophys J 102: 2585-2594, 2012.
7. Chao H, Zhou M, McIntosh A, Schroeder F, Kier AB. Acyl CoA binding protein and cholesterol differentially alter fatty acyl CoA utilization by microsomal acyl CoA: cholesterol transferase. J Lipid Res 44: 72-83, 2003.
8. Derikz JPM, Poeze M, van Bijnen AA, Buurman WA, Heineman E. Evidence for intestinal and liver epithelial cell injury in the early phase of sepsis. Shock 28: 544-548, 2007.
9. Fisher E, Weikert C, Klapper M, Lindner I, Mohlig M, Spranger J, Boeing H, Schrezenmeir J, Doring F. L-FABP T94A is associated with fasting triglycerides and LDL-cholesterol in women. Mol Genet Metab 91: 278-284, 2007.
10. Frolov A, Cho TH, Murphy EJ, Schroeder F. Isoforms of rat liver fatty acid binding protein differ in structure and affinity for fatty acids and fatty acyl CoAs. Biochemistry 36: 6545-6555, 1997.
11. Gajda AM, Zhou YX, Agellon LB, Fried SK, Kodukula S, Fortson W, Patel K, Storch J. Direct comparison of mice null for liver-or intestinal fatty acid binding proteins reveals highly divergent phenotypic responses to high fat feeding. J Biol Chem 288; 30330-30344, 2013.
12. Gao N, Qu X, Yan J, Huang Q, Yuan HY, Ouyang DS. L-FABP T94A decreased fatty acid uptake and altered hepatic triglyceride and cholesterol accumulation in Chang liver cells stably transfected with L-FABP. Mol Cell Biochem 345: 207-214, 2010.
13. Gariani K, Philippe J, Jornayvaz FR. Non-alcoholic liver disease and insulin resistance: from bench to bedside. Diabetes Metab 39: 16-26, 2013.
14. Gossett RE, Edmondson RD, Jolly CA, Cho TH, Russell DH, Knudsen J, Kier AB, Schroeder F. Structure and function of normal and transformed murine acyl CoA binding proteins. Arch Biochem Biophys 350: 201-213, 1998.
15. Guzman C, Benet M, Pisonero-Vaquero S, Moya M, Garcia-Mediavilla MV, Martinez-Chantar ML, Gonzalez-Gallego J, Castell JV, Sanchez-Campos S, Jover R. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARa; and repressed by C/EBPa: implicaiton in FABP1 down-regulation in nonalcoholic liver disease. Biochim Biophys Acta 1831: 803-818, 2013.
16. Hostetler HA, Balanarasimha M, Huang H, Kelzer MS, Kaliappan A, Kier AB, Schroeder F. Glucose regulates fatty acid binding protein interaction with lipids and PPARa. J Lipid Res 51: 3103-3116, 2010.
17. Hostetler HA, Lupas D, Tan Y, Dai J, Kelzer MS, Martin GG, Woldegiorgis G, Kier AB, Schroeder F. Acyl-CoA binding proteins interact with the acyl-CoA binding domain of mitochondrial carnitine palmitoyltransferase I. Mol Cell Biochem 355: 135-148, 2011.
18. Hostetler HA, McIntosh AL, Atshaves BP, Storey SM, Payne HR, Kier AB, Schroeder F. Liver type Fatty Acid Binding Protein (L-FABP) interacts with peroxisome proliferator activated receptor-a in cultured primary hepatocytes. J Lipid Res 50: 1663-1675, 2009.
19. Huang H, McIntosh AL, Martin GG, Landrock K, Landrock D, Gupta S, Atshaves BP, Kier AB, Schroeder F. Structural and functional interaction of fatty acids with human liver fatty acid binding protein (L-FABP) T94A variant. FEBS J 281: 2266-2283, 2014.
20. Huang H, McIntosh AL, Martin GG, Petrescu AD, Landrock K, Landrock D, Kier AB, Schroeder F. Inhibitors of fatty acid synthesis induce PPARa-regulated fatty acid b-oxidative enzymes: synergistic roles of L-FABP and glucose. PPAR Res 2013: 1-22, 2013.
21. Kabakibi A, Morse CR, Laposata M. Fatty acid ethyl esters and HepG2 cells: intracellular synthesis and release from the cells. J Lipid Res 39: 1568-1582, 1998.
22. Kamath S, Chavez AO, Gestaldelli A, Casiraghi F, Halff GA, Abrahamian GA, Davalli AM, Bastarrachea RA, Comuzzie AG, Guardado-Mendoza R, Jimenez-Ceja LM, Mattern V, Paez AM, Ricotti A, Tejero ME, Higgins PB, Rodriguez-Sanchez IP, Tripathy D, De-Fronzo RA, Dick EJ Jr, Cline GW, Folli F. Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One 6: e27617, 2011.
23. Kamijo-Ikemori A, Sugaya T, Matsui K, Yokoyama T, Kimura K. Roles of human liver type fatty acid binding protein in kidney disease clarified using human L-FABP chromosomal transgenic mice. Nephrology 16: 539-544, 2011.
24. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic liver disease. J Gastroenterol 48: 434-441, 2013.
25. Kazantzis M, Stahl A. Fatty acid transport proteins, implications in physiology and disease. Biochim Biophys Acta 1821: 852-857, 2012.
26. Martin GG, Atshaves BP, Huang H, McIntosh AL, Williams BW, Pai PJ, Russell DH, Kier AB, Schroeder F. Hepatic phenotype of liver fatty acid binding protein (L-FABP) gene ablated mice. Am J Physiol Gastrointest Liver Physiol 297: G1053-G1065, 2009.
27. Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem J 391: 549-560, 2005.
28. Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein (L-FABP) gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am J Physiol Gastrointest Liver Physiol 290: G36-G48, 2006.
29. Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein gene ablated female mice exhibit increased age-dependent obesity. J Nutr 138: 1859-1865, 2008.
30. Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein gene ablation enhances age-dependent weight gain in male mice. Mol Cell Biochem 324: 101-115, 2009.
31. Martin GG, Danneberg H, Kumar LS, Atshaves BP, Erol E, Bader M, Schroeder F, Binas B. Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the L-FABP gene. J Biol Chem 278: 21429-21438, 2003.
32. Martin GG, Hostetler HA, McIntosh AL, Tichy SE, Williams BJ, Russell DH, Berg JM, Spencer TA, Ball JA, Kier AB, Schroeder F. Structure and function of the sterol carrier protein-2 (SCP-2) N-terminal pre-sequence. Biochemistry 47: 5915-5934, 2008.
33. Martin GG, Huang H, Atshaves BP, Binas B, Schroeder F. Ablation of the liver fatty acid binding protein gene decreases fatty acyl CoA binding capacity and alters fatty acyl CoA pool distribution in mouse liver. Biochemistry 42: 11520-11532, 2003.
34. Martin GG, McIntosh AL, Huang H, Gupta S, Atshaves BP, Kier AB, Schroeder F. Human liver fatty acid binding protein (L-FABP) T94A variant alters structure, stability, and interaction with fibrates. Biochemistry 52: 9347-9357, 2013.
35. Martinez-Jimenez CP, Gomez-Lechon MJ, Castell JV, Jover R. Underexpressed coactivators PGC1 and SRC1 impair hepatocyte nuclear factor 4 funciton and promote dediffereniation in human hepatoma cells. J Biol Chem 281: 29840-29849, 2006.
36. Masters JR. Cell line misidentification: the beginning of the end. Nat Rev Cancer 10: 441-448, 2010.
37. McArthur MJ, Atshaves BP, Frolov A, Foxworth WD, Kier AB, Schroeder F. Cellular uptake and intracellular trafficking of long chain fatty acids. J Lipid Res 40: 1371-1383, 1999.
38. McIntosh AL, Atshaves BP, Landrock D, Landrock KK, Martin GG, Storey SM, Kier AB, Schroeder F. Liver fatty acid binding protein gene-ablation exacerbates weight gain in high fat fed female mice. Lipids 48: 435-448, 2013.
39. McIntosh AL, Atshaves BP, Hostetler HA, Huang H, Davis J, Lyuksyutova OI, Landrock D, Kier AB, Schroeder F. Liver type fatty acid binding protein (L-FABP) gene ablation reduces nuclear ligand distribution and peroxisome proliferator activated receptor-alpha activity in cultured primary hepatocytes. Arch Biochem Biophys 485: 160-173, 2009.
40. Moncecchi DM, Murphy EJ, Prows DR, Schroeder F. SCP-2 expression in mouse L-cell fibroblasts alters cholesterol uptake. Biochim Biophys Acta 1302: 110-116, 1996.
41. Murphy EJ, Edmondson RD, Russell DH, Schroeder F. Isolation and characterization of two distinct forms of liver fatty acid binding protein from the rat. Biochim Biophys Acta 1436: 413-425, 1999.
42. Nemecz G, Schroeder F. Selective binding of cholesterol by recombinant fatty acid-binding proteins. J Biol Chem 266: 17180-17186, 1991.
43. Newberry EP, Xie Y, Kennedy S, Buhman KK, Luo J, Gross RW, Davidson NO. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid binding protein gene. J Biol Chem 278: 51664-51672, 2003.
44. Peng XE, Wu YL, Lu QQ, Ju ZJ, Lin X. Two genertic variants in FABP1 and susceptibility to NAFLD in a Chinese population. Gene 500: 54-58, 2012.
45. Petrescu AD, Huang H, Martin GG, McIntosh AL, Storey SM, Landrock D, Kier AB, Schroeder F. Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARa regulated b-oxidative enzymes. Am J Physiol Gastrointest Liver Physiol 304: G241-G256, 2013.
46. Petrescu AD, McIntosh AL, Storey SM, Huang H, Martin GG, Landrock D, Kier AB, Schroeder F. High glucose potentiates L-FABP mediated fibrate induction of PPARa in mouse hepatocytes. Biochim Biophys Acta 1831: 1412-1425, 2013.
47. Pu L, Foxworth WB, Kier AB, Annan RS, Carr SA, Edmondson R, Russell D, Wood WG, Schroeder F. Isolation and characterization of 26-and 30-kDa rat liver proteins immunoreactive to anti-sterol carrier protein-2 antibodies. Protein Expr Purif 13: 337-348, 1998.
48. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sergeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46: 1081-1090, 2007.
49. Schoonjans K, Staels B, Auwerx J. Role of PPAR in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907-925, 1996.
50. Schroeder F, Jolly CA, Cho TH, Frolov AA. Fatty acid binding protein isoforms: structure and function. Chem Phys Lipids 92: 1-25, 1998.
51. Schroeder F, Petrescu AD, Huang H, Atshaves BP, McIntosh AL, Martin GG, Hostetler HA, Vespa A, Landrock K, Landrock D, Payne HR, Kier AB. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 43: 1-17, 2008.
52. Schulenberg-Schell H, Schafer P, Keuper HJ, Stanislawski B, Hoffmann E, Ruterjans H, Spener F. Interactions of fatty acids with neutral fatty-acid-binding protein from bovine liver. Eur J Biochem 170: 565-574, 1988.
53. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311, 2001.
54. Smathers RL, Galligan JJ, Shearn CT, Fritz KS, Mercer K, Ronis M, Orlicky DJ, Davidson NO, Petersen DR. Susceptibility of L-FABP-/-mice to oxidative stress in early-stage alcoholic liver. J Lipid Res 54: 1335-1345, 2013.
55. Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid binding proteins. Annu Rev Nutr 28: 18.1-18.23, 2008.
56. Storey SM, McIntosh AL, Huang H, Martin GG, Landrock KK, Landrock D, Payne HR, Kier AB, Schroeder F. Loss of intracellular lipid binding proteins differentially impacts saturated fatty acid uptake and nuclear targeting in mouse hepatocytes. Am J Physiol Gastrointest Liver Physiol 303: G837-G850, 2012.
57. Storey SM, McIntosh AL, Huang H, Martin GG, Landrock KK, Landrock D, Payne HR, Kier AB, Schroeder F. Intracellular cholesterol binding proteins enhance HDL-mediated cholesterol uptake in cultured primary mouse hepatocytes. Am J Physiol Gastrointest Liver Physiol 302: G824-G839, 2012.
58. Tailleux A, Wouters K, Staels B. Role of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821: 809-818, 2012.
59. Thumser AE, Wilton DC. Binding of natural and fluorescent lysophospholipids to wild-type and mutant rat liver fatty acid-binding protein and albumin. Biochem J 307: 305-311, 1995.
60. Velkov T. Interactions between human liver fatty acid binding protein and peroxisome proliferator activated receptor drugs. PPAR Res 2013: 1-14, 2013.
61. Vockley J, Rinaldo P, Bennett MJ, Matern D, Vladutiu GD. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol Genet Metab 71: 10-18, 2000.
62. von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nwroth PP, Bierhaus A, Humpert PM. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 40: 95-102, 2010.
63. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab Dispos 32: 1035-1042, 2003.
64. Wolfrum C, Borrmann CM, Borchers T, Spener F. Fatty acids and hypolipidemic drugs regulate PPARalpha and PPARgamma gene expresion via L-FABP: a signaling path to the nucleus. Proc Natl Acad Sci USA 98: 2323-2328, 2001.
65. Wolfrum C, Buhlman C, Rolf B, Borchers T, Spener F. Variation of liver fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. Biochim Biophys Acta 1437: 194-201, 1999.
66. Woodford JK, Behnke WD, Schroeder F. Liver fatty acid binding protein enhances sterol transfer by membrane interaction. Mol Cell Biochem 152: 51-62, 1995.
67. Yamada Y, Kato K, Oguri M, Yoshida T, Yokoi K, Watanabe S, Metoki N, Yoshida H, Satoh K, Ichihara S, Aoyagi Y, Yasunaga A, Park H, Tanaka M, Nozawa Y. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 21: 801-808, 2008.